Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Oncology

• Publication date

  1994-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1994.12.6.1193PMID 8201382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Clinical applications of fusion imaging in oncology.

  1994cited by this paper
• Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways.

  1994cited by this paper
• Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma.

  1994cited by this paper
• Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

  1993cited by this paper
• Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

  1993cited by this paper
• Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

  1993cited by this paper
• Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

  1993cited by this paper
• Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

  1993cited by this paper
• Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer.

  1992cited by this paper
• Engineered humanized dimeric forms of IgG are more effective antibodies

  1992cited by this paper
• A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.

  1992cited by this paper
• Immunogenetics of cell surface antigens of human cancer.

  1992cited by this paper
• Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers.

  1992cited by this paper
• Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

  1991cited by this paper
• Monoclonal antibodies in diagnosis and therapy

  1991cited by this paper
• Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions.

  1991cited by this paper
• Antibody-Drug Conjugates for Cancer Therapy

  1991cited by this paper
• Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody

  1991cited by this paper
• The role of stromal cells in tumor metastasis: a new link.

  1991cited by this paper
• Man-made antibodies

  1991cited by this paper
• Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors.

  1991cited by this paper
• The role of stromal cells in tumor metastasis: a new link.

  1991cited by this paper
• Recombinant toxins for cancer treatment.

  1991cited by this paper
• Therapy of lymphoma directed at idiotypes.

  1990cited by this paper
• Experimental studies of radioimmunodetection of cancer: an overview.

  1990cited by this paper
• Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

  1990cited by this paper
• Delivery of novel therapeutic agents in tumors: physiological barriers and strategies.

  1990cited by this paper
• Vascular attack as a therapeutic strategy for cancer

  1990cited by this paper
• Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

  1990cited by this paper
• Chelates and antibodies: current methods and new directions.

  1990cited by this paper
• A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

  1990cited by this paper
• Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain

  1989cited by this paper
• Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy.

  1989cited by this paper
• Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.

  1988cited by this paper
• Single-chain antigen-binding proteins.

  1988cited by this paper
• Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets.

  1986cited by this paper

• Theranostics targeting fibroblast activation protein in the pan‐cancer field

  2025cites this paper
• 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study

  2025cites this paper
• Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG/[18F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma

  2025cites this paper
• Clinical and Research Applications of FAPI Tracers: A Review.

  2025cites this paper
• Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

  2025cites this paper
• Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine.

  2025cites this paper
• [177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review.

  2025cites this paper
• Incoming novel radiotracer development: Fibroblast activation protein inhibitors for cancer diagnosis and treatment.

  2025cites this paper
• Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets

  2025cites this paper
• The molecular blueprint of targeted radionuclide therapy

  2025cites this paper
• Decoding tumors from fibroblast activation protein: A review of the latest diagnostic and therapeutic prospects.

  2025cites this paper
• Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress

  2025cites this paper
• Construction of 89Zr-Radiolabeled Melanin-Based Nanoprobes with FAP-Targeted Motifs for Tumor PET Imaging.

  2025cites this paper
• Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.

  2025cites this paper
• SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

  2025cites this paper
• Design and preclinical evaluation of 99mTc-Labeled dimer FAPI-46 derivatives as potential tumor radiotracers.

  2025cites this paper
• Revisiting the role of cancer-associated fibroblasts in tumor microenvironment

  2025cites this paper
• Advancements in colorectal cancer detection: The role of immuno‐positron emission tomography, immuno‐single‐photon emission computed tomography, and machine learning applications

  2024cites this paper
• Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

  2024cites this paper
• Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer

  2024cites this paper
• FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model.

  2024cites this paper
• From darkness to light: Targeting CAFs as a new potential strategy for cancer treatment.

  2024cites this paper
• Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging

  2024cites this paper
• Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression

  2024cites this paper
• Synthesis and Preclinical Evaluation of Novel 99mTc-Labeled FAPI-46 Derivatives with Significant Tumor Uptake and Improved Tumor-to-Nontarget Ratios.

  2024cites this paper
• Exploring the efficacy of FAPI PET/CT in the diagnosis and treatment management of colorectal cancer: a comprehensive literature review and initial experience

  2024influential citation
• Carborane-FAPI conjugate: A potential FAP-targeted boron agent with improved boron content.

  2024cites this paper
• Targeting the Devil: Strategies Against Cancer-Associated Fibroblasts in Colorectal Cancer.

  2024cites this paper
• Development of fibroblast activation protein-α radiopharmaceuticals: Recent advances and perspectives.

  2024cites this paper
• Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals

  2024influential citation
• CAR-T cell technologies that interact with the tumour microenvironment in solid tumours

  2024cites this paper
• Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.

  2024cites this paper
• 1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?

  2024cites this paper
• A Tumor‐Microenvironment‐Activatable Molecular Pro‐Theranostic Agent for Photodynamic and Immunotherapy of Cancer

  2023cites this paper
• Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.

  2023cites this paper
• Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.

  2023cites this paper
• Synthesis and Evaluation of 68Ga-Labeled (2S,4S)-4-Fluoropyrrolidine-2-Carbonitrile and (4R)-Thiazolidine-4-Carbonitrile Derivatives as Novel Fibroblast Activation Protein-Targeted PET Tracers for Cancer Imaging

  2023cites this paper
• Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

  2023cites this paper
• Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases

  2023cites this paper
• Design, Synthesis, and Evaluation of 18F-Labeled Tracers Targeting Fibroblast Activation Protein for Brain Imaging.

  2023cites this paper
• 225Ac-Labeled Antibody for Fibroblast Activation Protein-Targeted Alpha Therapy

  2023cites this paper
• FAPI PET/CT Imaging—An Updated Review

  2023influential citation
• Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy

  2023cites this paper
• Synthesis and Preclinical Evaluation of Novel 68Ga-Labeled (R)-Pyrrolidin-2-yl-boronic Acid-Based PET Tracers for Fibroblast Activation Protein-Targeted Cancer Imaging

  2023cites this paper
• The Potential of Fibroblast Activation Protein-Targeted Imaging as a Biomarker of Cardiac Remodeling and Injury

  2023cites this paper
• Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review

  2023cites this paper
• Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging

  2023cites this paper
• The Prognostic and therapeutic value and clinical implications of fibroblast activation protein-α as a novel biomarker in colorectal cancer

  2023cites this paper
• Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

  2023cites this paper
• Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies

  2023cites this paper
• Fibroblast Activation Protein: Pivoting Cancer/Chemotherapeutic Insight Towards Heart Failure.

  2023cites this paper
• What is new in cancer-associated fibroblast biomarkers?

  2023cites this paper
• Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements.

  2023cites this paper
• Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC

  2023cites this paper
• FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review

  2023cites this paper
• Clinical applications of fibroblast activation protein‐targeted theranostics in oncologic and nononcologic disease: Current status and future directions

  2023cites this paper
• A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

  2023cites this paper
• FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status

  2023cites this paper
• Anti‐cancer effect of targeting fibroblast activation protein alpha in glioblastoma through remodeling macrophage phenotype and suppressing tumor progression

  2022cites this paper
• Cancer-associated fibroblasts in acute leukemia

  2022cites this paper
• Design and characterization of fibroblast activation protein targeted pan-cancer imaging agent for fluorescence-guided surgery of solid tumors.

  2022cites this paper
• Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance

  2022cites this paper
• A theranostic approach for CAR-T cell therapy.

  2022cites this paper
• FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment

  2022cites this paper
• Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond

  2022cites this paper
• The application of FAPI-targeted theranostics in pancreatic cancer: a narrative review

  2022cites this paper
• Role of Serine Proteases at the Tumor-Stroma Interface

  2022cites this paper
• Fibroblast activation protein-based theranostics in pancreatic cancer

  2022cites this paper
• Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities

  2022cites this paper
• Screening and Preclinical Evaluation of Novel Radiolabeled Anti-Fibroblast Activation Protein-α Recombinant Antibodies

  2022cites this paper
• The heterogeneity of cancer‐associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment

  2022cites this paper
• Renal clearable polyfluorophore nanosensors for early diagnosis of cancer and allograft rejection

  2022cites this paper
• Molecular Immune Targeted Imaging of Tumor Microenvironment

  2022cites this paper
• Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy

  2022cites this paper
• Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics

  2022cites this paper
• An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

  2021cites this paper
• Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors

  2021cites this paper
• Fibroblast heterogeneity in prostate carcinogenesis.

  2021cites this paper
• Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management

  2021influential citation
• Nuklearmedizinische Theranostik

  2021cites this paper
• Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review

  2021cites this paper
• Preparation and Bioevaluation of 99mTc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein.

  2021cites this paper
• Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.

  2021cites this paper
• Tumor metastasis: Mechanistic insights and therapeutic interventions

  2021cites this paper
• The functional cross talk between cancer cells and cancer associated fibroblasts from a cancer mechanics perspective.

  2021cites this paper
• Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.

  2021cites this paper
• Cancer-Associated Fibroblasts: Implications for Cancer Therapy

  2021cites this paper
• In Vivo Imaging of Fibroblast Activity Using a 68Ga-Labeled Fibroblast Activation Protein Alpha (FAP-α) Inhibitor

  2021cites this paper
• New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

  2021influential citation
• Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.

  2021cites this paper
• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

  2021cites this paper
• Radioligands Targeting Fibroblast Activation Protein (FAP)

  2021cites this paper
• The role of fibroblast activation protein in health and malignancy

  2020cites this paper
• Tumor Microenvironment: Non-Hematopoietic Cells

  2020cites this paper
• FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?

  2020cites this paper
• FAP‐Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer Associated Fibroblasts

  2020cites this paper
• Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications.

  2020cites this paper
• Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography

  2020cites this paper
• Biomarkers for cancer-associated fibroblasts

  2020cites this paper
• Unmasking carcinoma-associated fibroblasts: Key transformation player within the tumor microenvironment.

  2020cites this paper